Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Status in Rechallenge of Immunotherapy
Han Hu, Ke Wang, Rong Jia, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 8, pp. 2428-2442
Open Access | Times Cited: 24

Showing 24 citing articles:

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy
Keyan Miao, Weici Liu, Jingtong Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
Hao Zhang, Yujun Hu, Tingting Wu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 4
Neoantigen immunotherapy: a novel treatment for bladder cancer
Runxin Lv, Zhenzhu Liu, M. Lv, et al.
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: A real-world study
Fen Liu, Guisen Yin, Ye Tao, et al.
International Immunopharmacology (2025) Vol. 152, pp. 114372-114372
Open Access
Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions?
Georgios Papageorgiou, Nikolaos Skouteris, Maria Grenzelia, et al.
Immunotherapy (2025), pp. 1-5
Closed Access
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature
Peng Ning, Shilan Liu, Hongyi Cao
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 752-752
Open Access | Times Cited: 2
Single Institution Experience with Immune Checkpoint Inhibitors in Vulvar and Vaginal Melanomas
Amrita Ladwa, Omar Elghawy, Varinder Kaur
Obstetrics and Gynecology International (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 2
Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases
Fei Cai, Di Wu, Junling Liu, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 177-183
Open Access | Times Cited: 1
Effective control of postoperative recurrence of pregnancy-related gastric cancer using anti-PD-1 as a monotherapy: a case report
Xu Liu, Xiaoqi Li, Chunchao Zhu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study
Yong-Gui Hong, Jun Liu, Ping Lu, et al.
The Oncologist (2024)
Open Access | Times Cited: 1
Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer
A. A. Musaelyan, Светлана Валентиновна Одинцова, Karina Oganyan, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 6, pp. 1271-1288
Open Access | Times Cited: 1
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure
Da Hyun Kang, Jisoo Lee, Subin Im, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3996-3996
Open Access | Times Cited: 1
Rechallenge of immunotherapy in non-small cell lung cancer patients — navigating indications and evolving perspectives
Magdalena Knetki‐Wróblewska, Izabela Chmielewska, Kamila Wojas‐Krawczyk, et al.
Oncology in Clinical Practice (2024)
Open Access
Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis
Kexin Tan, Aolin Wang, Yumin Zheng, et al.
Clinical & Translational Oncology (2024)
Closed Access
β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer
Qian Geng, Yingying Lu, Dongqing Li, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access
Neurological Complications of Immune Check Point Inhibitors
Sri Raghav Sista, Naveen Kumar Paramasivan, Divyanshu Dubey
Elsevier eBooks (2024)
Closed Access
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma
Omar Elghawy, Adam Barsouk, Reema Patel, et al.
Immunotherapy (2024) Vol. 16, Iss. 16-17, pp. 1069-1078
Closed Access
Rechallenge with immune checkpoint inhibitors therapy for patients with HCC-lot more to learn
George Lau
Hepatology International (2024)
Open Access
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study
Manyi Xu, Yanhua Wang, Ke Wang, et al.
Investigational New Drugs (2024)
Closed Access
Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in the Treatment of Esophageal Squamous Cell Cancer
Xueji Zhang, Jingze Zhang, Junyi He, et al.
Journal of Cancer (2024) Vol. 16, Iss. 3, pp. 943-951
Open Access
Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
Ranferi Ocaña‐Guzmán, Diego Osorio-Pérez, Leslie Chávez‐Galán
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1119-1119
Open Access | Times Cited: 1
Identification of CERS5 as a novel biomarker for prognosis and immunity in hepatocellular carcinoma: a bioinformatics analysis and functional validation study
Peng Qiu, Qibo Huang, Yunxiang Feng, et al.
Research Square (Research Square) (2023)
Open Access
Identification of CERS5 as a novel biomarker for prognosis and immunity in hepatocellular carcinoma: a bioinformatics analysis and functional validation study
Peng Qiu, Yunxiang Feng, Kai Zhao, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top